Tonix PharmaceuticalsÂ’ PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA

Responding to AtEase study results in military-related PTSD population, FDA agrees to work closely with Tonix to develop and review TNX-102 SL for PTSD as efficiently as possible NEW YORK, Dec. 19, 2016 -- (Healthcare Sales & Marketing Network) -- Tonix... Biopharmaceuticals, FDA Tonix Pharmaceuticals, TNX-102 SL, cyclobenzaprine, PTSD
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news